Ocugen, Inc. (OCGN)
| Market Cap | 607.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.83M |
| Shares Out | 216.57M |
| EPS (ttm) | -0.35 |
| PE Ratio | n/a |
| Forward PE | 15.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,940,934 |
| Open | 2.87 |
| Previous Close | 2.88 |
| Day's Range | 2.72 - 2.88 |
| 52-Week Range | 1.67 - 17.65 |
| Beta | 4.21 |
| Analysts | Buy |
| Price Target | 7.75 (+176.3%) |
| Earnings Date | Aug 5, 2022 |
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development st... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for OCGN stock is "Buy." The 12-month stock price forecast is 7.75, which is an increase of 176.29% from the latest price.
News
Here's How This Beaten-Down Stock Could 10X by 2024
A moonshot won't be necessary, but it'll require a bit of a pivot.
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therap...
Ocugen Provides Business Update & Second Quarter 2022 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Conference Call and Webcast Today at 8:30 a.m. ET
Ocugen Q2 Preview: Rebound Quarter Inbound?
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.
Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 202...
MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and ge...
Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today
Healthcare has become a bona fide stock picker's market this year.
Why Ocugen Is Climbing Today
India will soon be giving away doses of Covaxin for free.
Why Ocugen Stock Is Sinking Today
What goes up can come down.
Why Ocugen Stock Ascended Today
Its collaborator in India got a thumbs-up from regulators.
Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years
Ocugen Inc (NASDAQ: OCGN) announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Diseases. C...
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious...
Ocugen's partner Bharat Biotech's Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults
Ocugen Named Among Philadelphia's ‘2022 Best Places to Work'
MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen , Inc . (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals,...
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
Issuance of U.S. Patent No. 11,351,225 Further Enhances Ocugen's Gene Therapy Intellectual Property Portfolio Issuance of U.S. Patent No. 11,351,225 Further Enhances Ocugen's Gene Therapy Intellectual P...
Why Ocugen Stock Flopped on Friday
Shareholders could be hit with a high degree of stock dilution soon.
Ocugen, Inc. to Present at BIO International Convention 2022
MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccin...
2 Struggling Stocks That Aren't Likely to Recover Anytime Soon
Don't buy the dip on these stocks.
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Ocugen Diversifies Its Pipeline With New Cell Therapy Platform
Ocugen Inc (NASDAQ: OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage). Recently, the FDA ...
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines
OCGN Stock Falls Despite Positive FDA Update
Shares of the biotech company are falling despite news that the FDA has cleared it to resume clinical trials of its Covid-19 vaccine. The post OCGN Stock Falls Despite Positive FDA Update appeared first...
FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial
The FDA has lifted the clinical hold on Ocugen Inc's (NASDAQ: OCGN) Phase 2/3 trial, OCU-002, for Covaxin (BBV152), a whole virus inactivated COVID-19 vaccine candidate. In April, the agency paused the...
Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines...
Ocugen shares jump premarket after FDA lifts clinical hold on trial of COVID-19 vaccine candidate
Ocugen Inc. shares OCGN, -0.45% jumped 9% premarket Monday, after the biotech said the Food and Drug Administration has lifted its clinical hold on Ocugen's Phase 2/3 trial of its COVID-19 vaccine candi...
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)
Dosing to Resume Immediately Dosing to Resume Immediately